相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective
Baichen Xiong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity
Jacob Stuckey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma
Kulandaimanuvel Antony Michealraj et al.
CELL (2020)
The Critical Role of Passive Permeability in Designing Successful Drugs
Li Di et al.
CHEMMEDCHEM (2020)
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma
Roman Groisberg et al.
LANCET ONCOLOGY (2020)
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Alfredo M. Valencia et al.
NATURE CELL BIOLOGY (2019)
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.
Xiao-Nan Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Jennifer K. Lue et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Faizaan Mohammad et al.
NATURE MEDICINE (2017)
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Andrea Piunti et al.
NATURE MEDICINE (2017)
QuickStats: Brain Cancer Death Rates Among Children and Teens Aged 1–19 Years,* by Sex† and Age Group — United States, 2013–2015
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
Daisuke Honma et al.
CANCER SCIENCE (2017)
Genome Regulation by Polycomb and Trithorax: 70 Years and Counting
Bernd Schuettengruber et al.
CELL (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors
Xiaobao Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
Kevin W. Kuntz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
Alexei Brooun et al.
NATURE COMMUNICATIONS (2016)
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors
Ping Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Zoran Rankovic
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
AT-01 * THERAPEUTIC TARGETING OF INI1 DEFICIENCY IN PEDIATRIC ATRT: A PRE-CLINICAL STUDY UTILIZING PATIENT DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODELS
H. Lindsay et al.
NEURO-ONCOLOGY (2015)
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
Daniel Zingg et al.
NATURE COMMUNICATIONS (2015)
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
Jessamy C. Tiffen et al.
ONCOTARGET (2015)
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Katherine C. Helming et al.
CANCER CELL (2014)
Demystifying Brain Penetration in Central Nervous System Drug Discovery
Li Di et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
How hydrogen bonds impact P-glycoprotein transport and permeability
Prashant V. Desai et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds
Stephen A. Hitchcock
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
Tim J. Wigle et al.
FEBS LETTERS (2011)
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Boris G. Wilson et al.
CANCER CELL (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Strategies to assess blood-brain barrier penetration
Li Di et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Genome regulation by polycomb and trithorax proteins
Bernd Schuettengruber et al.
CELL (2007)
Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding
Tom Young et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Long-term survival with metastatic cancer to the brain
WA Hall et al.
MEDICAL ONCOLOGY (2000)
分享论文
